Action NOV NOVO NORDISK A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Novo Nordisk A/S Xetra

Actions

NOV

DK0062498333

Marché Fermé - Xetra
Autres places de cotation
 17:35:36 04/07/2024 		Pré-ouverture 07:46:30
130,5 EUR +2,53% Graphique intraday de Novo Nordisk A/S 129,4 -0,84%
04/07 ETF de la semaine : Investir sur les tendances fortes avec la thématique du momentum Our Logo
04/07 NOVO NORDISK : Deutsche Bank à l'achat ZD

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Novo Holdings invests in MATR Foods expansion within plant-based fungi food
AQ
Novo Nordisk A/S - share repurchase programme
GL
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
GL
New US fill finish facility receives $4.1 billion investment
AQ
Dewpoint Therapeutics Strengthens Collaboration with Novo Nordisk to Accelerate Drug Discovery
AQ
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
GL
Novo Nordisk A/S - share repurchase programme
GL
Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month
AQ
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
GL
World's first weekly insulin injection coming to Canada in 2 weeks, manufacturer says
AQ
Novo Nordisk A/S - share repurchase programme
GL
Haemophilia drug could reduce treated bleeding episodes
AQ
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
AQ
Novo Nordisk A/S - share repurchase programme
GL
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
AQ
Novo Nordisk A/S - share repurchase programme
GL
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
Novo Nordisk A/S - share repurchase programme
GL
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NOVO B
  4. Action NOV
  5. Actualités Novo Nordisk A/S
  6. Communiqués